Luetke A, Meyers PA, Lewis A, Juergens H (2014). “Osteosarcoma treatment—where do we stand? A state of the art review”. 《Cancer Treat Rev》 40 (4): 523–532. doi:10.1016/j.ctrv.2013.11.006. PMID24345772.
He X, Pang Z, Zhang X, Lan T, Chen H, Chen M, Yang H, Huang J, Chen Y, Zhang Z, Jing W, Peng R, Zhang H (September 2018). “Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis”. 《The American Journal of Surgical Pathology》 42 (9): 1143–1155. doi:10.1097/PAS.0000000000001125. PMID30001240. S2CID51618887.
Papalas JA, Balmer NN, Wallace C, Sangüeza OP (June 2009). “Ossifying dermatofibroma with osteoclast-like giant cells: report of a case and literature review”. 《Am J Dermatopathol》 31 (4): 379–83. doi:10.1097/DAD.0b013e3181966747. PMID19461244.
Bech-Nielsen; S.; Haskins; M. E.; 외. (1978). “Frequency of osteosarcoma among first-degree relatives of St. Bernard dogs”. 《J Natl Cancer Inst》 60 (2): 349–53. doi:10.1093/jnci/60.2.349. PMID271748.지원되지 않는 변수 무시됨: |name-list-style= (도움말)
Ranen E, Lavy E, Aizenberg I, Perl S, Harrus S (2004). “Spirocercosis-associated esophageal sarcomas in dogs. A retrospective study of 17 cases (1997-2003)”. 《Veterinary Parasitology》 119 (2–3): 209–221. doi:10.1016/j.vetpar.2003.10.023. PMID14746980.
Loukopoulos P, Thornton JR, Robinson WF (May 2003). “Clinical and pathologic relevance of p53 index in canine osseous tumors”. 《Veterinary Pathology》 40 (3): 237–48. doi:10.1354/vp.40-3-237. PMID12724563.
Tomlin JL, Sturgeon C, Pead MJ, Muir P (2000년 7월 29일). “Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs”. 《The Veterinary Record》 147 (5): 129–32. doi:10.1136/vr.147.5.129. PMID10958534. S2CID35757270.
Luetke A, Meyers PA, Lewis A, Juergens H (2014). “Osteosarcoma treatment—where do we stand? A state of the art review”. 《Cancer Treat Rev》 40 (4): 523–532. doi:10.1016/j.ctrv.2013.11.006. PMID24345772.
He X, Pang Z, Zhang X, Lan T, Chen H, Chen M, Yang H, Huang J, Chen Y, Zhang Z, Jing W, Peng R, Zhang H (September 2018). “Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis”. 《The American Journal of Surgical Pathology》 42 (9): 1143–1155. doi:10.1097/PAS.0000000000001125. PMID30001240. S2CID51618887.
Papalas JA, Balmer NN, Wallace C, Sangüeza OP (June 2009). “Ossifying dermatofibroma with osteoclast-like giant cells: report of a case and literature review”. 《Am J Dermatopathol》 31 (4): 379–83. doi:10.1097/DAD.0b013e3181966747. PMID19461244.
Bech-Nielsen; S.; Haskins; M. E.; 외. (1978). “Frequency of osteosarcoma among first-degree relatives of St. Bernard dogs”. 《J Natl Cancer Inst》 60 (2): 349–53. doi:10.1093/jnci/60.2.349. PMID271748.지원되지 않는 변수 무시됨: |name-list-style= (도움말)
Ranen E, Lavy E, Aizenberg I, Perl S, Harrus S (2004). “Spirocercosis-associated esophageal sarcomas in dogs. A retrospective study of 17 cases (1997-2003)”. 《Veterinary Parasitology》 119 (2–3): 209–221. doi:10.1016/j.vetpar.2003.10.023. PMID14746980.
Loukopoulos P, Thornton JR, Robinson WF (May 2003). “Clinical and pathologic relevance of p53 index in canine osseous tumors”. 《Veterinary Pathology》 40 (3): 237–48. doi:10.1354/vp.40-3-237. PMID12724563.
Tomlin JL, Sturgeon C, Pead MJ, Muir P (2000년 7월 29일). “Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs”. 《The Veterinary Record》 147 (5): 129–32. doi:10.1136/vr.147.5.129. PMID10958534. S2CID35757270.
He X, Pang Z, Zhang X, Lan T, Chen H, Chen M, Yang H, Huang J, Chen Y, Zhang Z, Jing W, Peng R, Zhang H (September 2018). “Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis”. 《The American Journal of Surgical Pathology》 42 (9): 1143–1155. doi:10.1097/PAS.0000000000001125. PMID30001240. S2CID51618887.
Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, Fink K, Peck SD, Stevens SL, Kelly CM, Camozzi AB (June 2003). “Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity”. 《Annals of Surgical Oncology》 10 (5): 498–507. doi:10.1245/ASO.2003.03.061. PMID12794015. S2CID32721347.
Tomlin JL, Sturgeon C, Pead MJ, Muir P (2000년 7월 29일). “Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs”. 《The Veterinary Record》 147 (5): 129–32. doi:10.1136/vr.147.5.129. PMID10958534. S2CID35757270.